Nissui Pharmaceutical Co Ltd
TSE:4550
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nissui Pharmaceutical Co Ltd
Revenue
Nissui Pharmaceutical Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Nissui Pharmaceutical Co Ltd
TSE:4550
|
Revenue
¥16.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Hoya Corp
TSE:7741
|
Revenue
¥916.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
H
|
Hogy Medical Co Ltd
TSE:3593
|
Revenue
¥37.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
A
|
Asahi Intecc Co Ltd
TSE:7747
|
Revenue
¥129.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
19%
|
CAGR 10-Years
13%
|
|
|
Mani Inc
TSE:7730
|
Revenue
¥39.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
|
Nipro Corp
TSE:8086
|
Revenue
¥652.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
Nissui Pharmaceutical Co Ltd
Glance View
Nissui Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of culture media and diagnostic reagents for medical institutions, research organizations, and food industries. The company is headquartered in Taito-Ku, Tokyo-To and currently employs 250 full-time employees. is a Japan-based company mainly engaged in the manufacture, purchase and sale of clinical diagnostic drugs, industrial diagnostic drugs, pharmaceuticals, among others. The firm operates through two business segments. The Diagnostic Drug segment is involved in the manufacture, purchase and sale of culture media, clinical diagnostic drugs, industrial diagnostic drugs and raw materials for medical institutions, research institutions and industrial facilities, as well as the purchase and sale of testing equipment and other equipment. The Pharmaceutical segment is involved in the manufacture, purchase and sale of pharmaceuticals and health foods for pharmacies and drugstores. The Company’s main products include clinical diagnostic drugs, industrial diagnostic drugs such as compactdry, pharmaceuticals such as therapeutics, nourishing tonics and health foods.
See Also
What is Nissui Pharmaceutical Co Ltd's Revenue?
Revenue
16.7B
JPY
Based on the financial report for Mar 31, 2022, Nissui Pharmaceutical Co Ltd's Revenue amounts to 16.7B JPY.
What is Nissui Pharmaceutical Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
5%
Over the last year, the Revenue growth was 39%. The average annual Revenue growth rates for Nissui Pharmaceutical Co Ltd have been 10% over the past three years , 5% over the past five years .